Overview

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Status:
RECRUITING

Trial end date:
2031-02-01

Target enrollment:

Participant gender:

Summary

To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Aadi Bioscience

Treatments:

Gemcitabine